"Performance" GRANDPHARMA's interim net profit of 1.169 billion yuan fell by 25% and no dividend was declared
GRANDPHARMA (00512.HK) announced its interim results for the six months ending in June, with revenue of HKD 6.107 billion, an increase of 1% year-on-year. It recorded a net profit of HKD 1.169 billion, a decline of 25%, with earnings per share of HKD 0.3338. No dividend was declared.
Excluding the impact of the Telix investment on profits, the normalized profit for the period was approximately HKD 1.017 billion, a decline of 5.9%, mainly affected by the price reduction from the tenth batch of centralized procurement and the increase in marketing expenses due to the accelerated launch of new products
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments